Can-Fite has a number of drugs in various stages of research and development. The pipeline drugs are synthetic, highly specific agonists and an allosteric modulator, all target the A3 adenosine receptor. All drugs are orally bioavailable with an excellent safety profile.
CF101, Can-Fite’s lead compound, is an oral drug that has been successfully tested in animal models and is currently in advanced stages of clinical development for Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where CF101 has been given as a stand alone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the interim analysis of the Phase II/III clinical studies in Psoriasis were successfully concluded showing efficacy and safety of CF101.
Can-Fite holds 82% in OphthaliX Inc. (OTCBB: OPLI) which develops CF101 for ophthalmic indications, including Dry Eye Syndrome, Glaucoma and Uveitis.
CF102, Can-Fite’s second drug candidate, is an oral drug currently being developed for the treatment of hepatocellular carcinoma (Primary Liver Cancer).
CF602, Can-Fite’s next generation compound, is an allosteric modulator at the A3AR. This compound has a robust anti-inflammatory effects proven in a variety of autoimmune inflammatory and inflammatory animal models, and will be developed as a second generation anti-inflammatory drug. .